More Free Market Health Care
Pfizer is planning on selling its potentilal blockbuster new drug, torcetrapib, raises the level of "good" high-density cholesterol only in combination with Lipitor, it's statin. Statin's lower LDL, the bad cholesterol.
Not coincidentally, Lipitor will soon go generic.
I think these kinds of shenanigans are more a result of a distorted market, than a problem of a market based approaced to health care (and pharmaceuticals in particular)
As the article puts it:
When the F.D.A. reviews a new medicine, its main concerns are safety andMaybe that should change.
efficacy. The agency has little authority over the cost of new drugs or
ability to encourage competition among drug companies.
1 Comments:
Lipitor doesn't lose patent protection for quite a while, actually. It's complicated, but 5-7 years at the minimum. Longer if it gets a new indications
Post a Comment
<< Home